U of T and McMaster Launch Early-Stage Life Sciences Venture Fund in Collaboration with Genesys Capital

On July 8, 2026, a collaborative initiative was announced involving the University of Toronto (U of T), McMaster University, Venture Ontario, and veteran investor Genesys Capital to establish the Genesys University Seed Fund. This venture capital fund aims to provide crucial early-stage funding for life sciences startups in Ontario and enhance Canada's health economy. The fund has already raised over $30 million in commitments from various supporters, including U of T, McMaster, and RBC.

U of T President Melanie A. Woodin emphasized that Canada has ample talent and innovative ideas but lacks the capital necessary to scale them. Therefore, the fund will serve as a vital conduit to transform university research into viable companies, improving patient care and creating jobs. Similarly, McMaster President Susan Tighe remarked on the importance of universities in driving the economy through translating research into practical applications that improve healthcare.

Ontario boasts one of North America's largest life sciences clusters, with around 76,000 skilled workers in over 2,000 firms. Nevertheless, it struggles with limited early-stage investment capital compared to other regions, especially in the U.S. This gap leads many Canadian innovators to relocate to entrepreneurial hubs like Boston and Silicon Valley. The Genesys University Seed Fund aims to remedy this situation by providing necessary early-stage venture capital, encouraging more startups to remain in Ontario.

Vic Fedeli, Ontario's Minister of Economic Development, highlighted the fund's potential in bridging the gap from breakthrough discoveries to commercialization, facilitating the development of life sciences companies in the province. This initiative is closely aligned with Venture Ontario’s goal of strengthening Ontario’s economy through innovative startups.

Genesys Capital, managing the fund, has a 25-year track record of investing over $400 million in life sciences ventures. Co-founder Kelly Holman asserted that access to capital is critical for a healthy economy, particularly in the fast-evolving life sciences sector. The fund will not only support startups but also allow U of T and McMaster to reinvest returns into further research and innovation, creating a cyclic effect that stimulates additional startup activity.

The Genesys University Seed Fund will further bolster Ontario’s status as a global leader in life sciences innovation. The initiative has already garnered significant attention, with both universities being recognized for their successful entrepreneurship track records and contributions to impactful health technology startups. U of T has produced over 1,500 venture-backed startups in five years, raising over $14 billion, while McMaster has supported nearly 400 startups, featuring successful exits like Fusion Pharmaceuticals.

As this initiative progresses, the Genesys University Seed Fund will continue seeking investments to expand its size to $40 million. This collaborative effort signals a strong commitment to fostering life sciences commercialization in Ontario, positioning the province as an attractive destination for both startups and investors in the evolving health tech landscape. Interested partners and investors are encouraged to reach out to Genesys Capital for more information on involvement opportunities.